MTPA announces long-term findings from post-marketing safety study of Radicava
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Strengthens investment in channels of the future to expand patient reach
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Subscribe To Our Newsletter & Stay Updated